New study aims to lower relapse risk in testicular cancer patients
NCT ID NCT02341989
First seen Jan 05, 2026 · Last updated May 01, 2026 · Updated 17 times
Summary
This study compares two chemotherapy treatments for men with stage I seminoma testicular cancer who have risk factors for relapse. Participants receive either one course of carboplatin (standard care) or a stronger combination of three drugs (BEP). The goal is to see if BEP leads to fewer cancer recurrences and to compare side effects and quality of life. About 348 men aged 18-59 are taking part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SEMINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Institutt for kreftforskning og molekylær medisin, St Olavs Hospital
Trondheim, Norway
-
St. Olavs University hospital HF
Trondheim, Norway
Conditions
Explore the condition pages connected to this study.